Mannitol is an osmotic diuretic indicated for the reduction of intracranial pressure and treatment of cerebral edema,, among other approved uses. It is available as injection and kits for intravenous use. MedsAcross supplies Mannitol for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
From the regulator-approved product information. Each section names its source.
OSMITROL is indicated for: • The reduction of intracranial pressure and treatment of cerebral edema, • The reduction of elevated intraocular pressure. OSMITROL is an osmotic diuretic, indicated for the reduction of: • intracranial pressure and treatment of cerebral edema. • elevated intraocular pressure.
Source: US FDA prescribing information
Mannitol, when administered intravenously, exerts its osmotic diuretic effect as a solute of relatively small molecular size being largely confined to the extracellular space. Mannitol hinders tubular reabsorption of water and enhances excretion of sodium and chloride by elevating the osmolarity of the glomerular filtrate. This increase in extracellular osmolarity affected by the intravenous administration of mannitol will induce the movement of intracellular water to the extracellular and vascular spaces. This action underlies the role of mannitol in reducing intracranial pressure, intracranial edema, and intraocular pressure.
Source: US FDA prescribing information
Administration Instructions: • For intravenous infusion preferably into a large central vein. • Prior to administration, evaluate renal, cardiac and pulmonary status, and correct fluid and electrolyte imbalances. Recommended Dosage: • The dosage, concentration and rate of administration depend on the age, weight and condition of the patient, including fluid requirement, urinary output and concomitant therapy. • Reduction of Intracranial Pressure: 0.25 gram/kg administered every 6 to 8 hours as an intravenous infusion over 30 minutes. • Reduction of Intraocular Pressure: 1.5 to 2 grams/kg of a 15% or 20% w/v solution as a single dose administered intravenously over at least 30 minutes.
Source: US FDA prescribing information
OSMITROL is contraindicated in patients with: • Known hypersensitivity to mannitol • Anuria • Severe hypovolemia • Pre-existing severe pulmonary vascular congestion or pulmonary edema • Active intracranial bleeding except during craniotomy • Known hypersensitivity to mannitol. • Anuria. • Severe hypovolemia. • Pre-existing severe pulmonary vascular congestion or pulmonary edema. • Active intracranial bleeding except during craniotomy.
Source: US FDA prescribing information
• Hypersensitivity Reactions, including anaphylaxis: Stop infusion immediately if hypersensitivity reactions develop. • Renal Complications Including Renal Failure: Risk factors include pre-existing renal failure, concomitant use of nephrotoxic drugs or other diuretics. Avoid use of nephrotoxic drugs. Discontinue OSMITROL if renal function worsens. • Central Nervous System (CNS) Toxicity: Confusion, lethargy and coma may occur during or after infusion. Concomitant neurotoxic drugs may potentiate toxicity. Avoid use of neurotoxic drugs. Discontinue OSMITROL if CNS toxicity develops. • Fluid and Electrolyte Imbalances, Hyperosmolarity: Hypervolemia may exacerbate congestive heart failure, hyponatremia can lead to encephalopathy, hypo/hyperkalemia can result in cardiac adverse reactions in sensitive patients. Discontinue OSMITROL if fluid and/or electrolyte imbalances occur.
Source: US FDA prescribing information
The following adverse reactions from voluntary reports or clinical studies have been reported with OSMITROL. Because many of these reactions were reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. • Hypersensitivity reactions: cardiac arrest, anaphylaxis, hypotension, dyspnea, hypertension, pyrexia, chills, sweating, cough, musculoskeletal stiffness, myalgia, urticarial/rash, pruritus, generalized pain, discomfort, nausea, vomiting, and headache.
Source: US FDA prescribing information
• Nephrotoxic Drugs and Diuretics: May increase the risk of renal failure, avoid concomitant use. • Neurotoxic Drugs: May potentiate CNS toxicity of mannitol, avoid concomitant use. • Drugs Affected by Electrolyte Imbalances: May result in cardiac adverse reactions, monitor serum electrolytes and discontinue OSMITROL if cardiac status worsens. • Renally Eliminated Agents: Concomitant use may decrease the effectiveness of agents that undergo significant renal elimination. However, concomitant use of mannitol and lithium may increase risk of lithium toxicity. If concomitant use is necessary, frequently monitor lithium concentrations and for signs of toxicity.
Source: US FDA prescribing information
Store at room temperature (25°C), brief exposure up to 40°C does not adversely affect the product.
Source: US FDA prescribing information
For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
7 presentations of Mannitol, sorted by availability.
| Medicine | Manufacturer | Register | Availability |
|---|---|---|---|
| Mannitol 12.5 g/50 mL injectionIntravenousGeneric name | — | US FDA | Available on request |
| Mannitol 100 g/500 mL injectionIntravenousGeneric name | — | US FDA | Available on request |
| Mannitol 50 g/250 mL injectionIntravenousGeneric name | — | US FDA | Available on request |
| Aridol Bronchial Challenge Test Kit kit | Methapharm | US FDA | Available on request |
| Osmitrol 100 g/500 mL injectionIntravenous | Baxter Healthcare | US FDA | Available on request |
| Osmitrol 50 g/250 mL injectionIntravenous | Baxter Healthcare | US FDA | Available on request |
| Osmitrol 50 g/500 mL injectionIntravenous | Baxter Healthcare | US FDA | Available on request |
2 brand names across 1 markets.
United States
Approval facts from US FDA, EMA and CDSCO data, and registration status by country where we hold register data.
Conditions linked to Mannitol in public data. This is not a list of approved uses, see the clinical information.
Yes, on request. MedsAcross lists 7 presentations of Mannitol and sources them for licensed hospitals, importers and physicians against valid import documents.
The catalogue lists 2 brand names for Mannitol, including Aridol Bronchial Challenge Test Kit, Osmitrol.
Yes. The US FDA first approved Mannitol on 8 June 1964, according to Drugs@FDA.
Yes. Mannitol has a central EU marketing authorisation (status: authorised), according to European Medicines Agency data.
No listed presentation of Mannitol is recorded as needing a cold chain. Storage conditions are shown on each presentation page.
Mannitol is classified under ATC code A06AD16 (Mannitol).
Tell us the strength, quantity and destination country. Our team replies with availability, lead time and the import documents needed.